BIOPHARMARK

Gembloux ·KBO/BCE: BE 0779.946.613

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
30-06-2025	31-01-2026	19-12-2025	43 d early	2025-00585644
30-06-2024	31-01-2025	31-01-2025	on the day	2025-00019066
30-06-2023	31-01-2024	31-01-2024	on the day	2024-00016703
30-06-2022	31-01-2023	27-01-2023	4 d early	2023-00005713

Metric	This company	Sector median	Position in the sector
Solvency	57.9%	55.5%	better than 52% of 4723 sector peers
Net result	€36k	€38k	better than 49% of 4722 sector peers
Equity	€102k	€64k	better than 64% of 4723 sector peers
Gross operating margin	€71k	€61k	better than 56% of 4715 sector peers
Staff costs	€17k	€6k	higher than 60% of 380 sector peers

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€177k
Fixed assets	21/28	€11k
Tangible fixed assets	22/27	€11k
Financial fixed assets	28	€205
Current assets	29/58	€165k
Amounts receivable within one year	40/41	€23k
Cash & bank	54/58	€138k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€177k
Equity	10/15	€102k
Contributions / capital	10/11	€2k
Accumulated profits (losses)	14	€100k
Amounts payable	17/49	€74k
Amounts payable within one year	42/48	€74k
Trade debts payable within one year	44	€2k
Income statement
Gross operating margin	9900	€71k
Operating result	9901	€49k
Financial charges	65	€3k
Result before taxes	9903	€47k
Income taxes	67/77	€10k
Net result for the period	9904	€36k
Result to be appropriated	9905	€36k

Summary